Publications by authors named "Marc Issandou"

Claim this Profile
S
Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Michael K Hansen, Matthew J McVey, Ray F White, Jeffrey J Legos, Jean-Marie Brusq, Marc Issandou

J Cardiovasc Pharmacol Ther· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.
François Briand, Morgan Tréguier, Agnès André, Didier Grillot, Marc Issandou

J Lipid Res· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Marc Issandou, Anne Bouillot, Jean-Marie Brusq, Marie-Claire Forest, Didier Grillot

Eur J Pharmacol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and evaluation of a novel series of 2,3-oxidosqualene cyclase inhibitors with low systemic exposure, relationship between pharmacokinetic properties and ocular toxicity.
Marie-Hélène Fouchet, Frédéric Donche, Christelle Martin, Anne Bouillot, Christophe Junot, Marc Issandou

Bioorg Med Chem· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological regulation of low density lipoprotein receptor expression: current status and future developments.
Marc Issandou

Pharmacol Ther· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine.
Jean-Marie Brusq, Nicolas Ancellin, Pascal Grondin, Raphaelle Guillard, Sandrine Martin, Marc Issandou

J Lipid Res· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene: lanosterol cyclase activity.
Nicolas Venteclef, Raphaelle Guillard, Marc Issandou

Biochem Pharmacol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-regulation of low-density lipoprotein receptor in human hepatocytes is induced by sequestration of free cholesterol in the endosomal/lysosomal compartment.
Marc Issandou, Raphaëlle Guillard, Anne-Benedicte Boullay, Valerie Linhart, Elvira Lopez-Perez

Biochem Pharmacol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The steroidal analog GW707 activates the SREBP pathway through disruption of intracellular cholesterol trafficking.
Jessie Zhang, Nicole Dudley-Rucker, Jan R Crowley, Elvira Lopez-Perez, Marc Issandou

J Lipid Res· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis